ArticleCureus2025
Effect of Sunflower Lecithin Supplementation on Meibomian Gland Function in Adults With Dry Eye Disease.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDry eye disease (DED), often associated with meibomian gland dysfunction (MGD), affects millions globally, yet effective treatments remain limited. Sunflower lecithin, rich in phosphatidylcholine, may enhance lipid secretions from the meibomian glands, potentially stabilizing the tear film and reducing evaporative loss. We tested the hypothesis that sunflower lecithin supplementation can improve the signs and symptoms of DED in adults with MGD.
methodsIn this double-blind, single-center clinical trial, 31 patients with DED were randomized in a 2:1 ratio to receive either sunflower lecithin (4,800 mg/day) or placebo (4,000 mg olive oil/day) for 90 days. At baseline and the end of the study, DED symptoms were evaluated using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire. DED signs were evaluated through tear film breakup time (TBUT), meibomian gland score (MGS), and ocular surface inflammation, measured via matrix metalloproteinase-9 (MMP-9) detection using the InflammaDry test (QuidelOrtho, San Diego, USA). For both groups, mean changes were calculated, and unpaired t-tests were used to compare mean values between groups with statistical significance set at P<0.05. Additionally, the mean difference between the active and placebo groups was calculated for each outcome to quantify the magnitude of improvement or worsening in the active group relative to placebo. Results: Active and placebo groups showed decreases in SPEED scores with mean changes of -3.21 ± 1.47 and -1.50 ± 3.34 points, respectively, resulting in a mean difference of -1.71 (95% CI: -5.36 to 1.94; P=0.29). TBUT, MGS, and InflammaDry results improved in both groups but showed no significant differences between groups. Both groups exhibited improvements across all metrics with no significant differences.
conclusionSunflower lecithin supplementation did not demonstrate a significant therapeutic benefit over placebo in improving MGD-related DED signs or symptoms. Further research with larger sample sizes, longer follow-up, and combination therapies is recommended to explore the potential role of phospholipids in DED management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.